Abstract
CD137 is a member of the TNF receptor family and it has originally been identified as a potent T cell costimulatory molecule. Recently, it has become evident that CD137 signals can also inhibit T cell activity under certain conditions. The CD137 receptor/ligand system has the ability to signal bidirectionally. CD137 ligand is also expressed as a cell membrane protein and it can also transduce signals into the cells it is expressed on, referred to as reverse signaling. The signals through CD137 ligand are activating or costimulatory for antigen presenting cells (APC). Together with CD137, which can deliver costimulatory signals to T cells, the CD137 receptor/ligand pair can therefore form a potent proinflammatory system enhancing immune reactions by stimulating APC as well as T cells. CD137 ligand signals, however, negatively regulate T cell proliferation and survival, and it is possible that this activity of CD137 ligand participates in the termination of immune responses. The bidirectional signaling capacity allows the CD137 receptor/ligand system to mediate extensive crosstalk between immune cells and between immune and non-immune cells. CD137 (4-1BB, induced by lymphocyte activation, ILA) is a member of the tumor necrosis factor (TNF) receptor family (Kwon and Weissman, 1989; Schwarz et al., 1993). CD137 has originally been identified as a potent T cell costimulatory molecule and a promising target for immunotherapy of cancer (Melero et al., 1997). Recent evidence also demonstrates a role for CD137 signaling in T cells for inhibiting immune responses and autoimmune disease (Foell et al., 2003; 2004). The other chapters of this book and several recent reviews provide a comprehensive overview over the various activities of CD137 signaling on immune functions and their potential therapeutic applications (Al-Shamkhani, 2004; Croft, 2003; Kwon et al., 2000; Sica and Chen, 2000). Interaction of CD137 with CD137 ligand, however, not only initiates a signal into the CD137-expressing cell but also into the CD137 ligand-expressing
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have